Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
| Sponsor Type | Funding Program Title | Amount and Duration | Description | Deadline | |
|---|---|---|---|---|---|
| Tri-Agency | CIHR Operating Grant: Bringing Rare Disease Gene Therapies to Clinical Trial Readiness | Up to $284,375 per year for up to 4 years. | This will support research to bridge the current gap between model organisms/systems and clinical trials for rare disease drugs in Canada, ultimately increasing the capacity to bring gene therapies to clinic. Key elements of this research will include: Training and Capacity-Building; Knowledge Mobilization. | Letter of Intent: September 20, 2023. Full Application (by invitation): February 13, 2023. | |
| Tri-Agency | CIHR Catalyst Grant: Health Impacts of Gambling and Gaming | Up to $100,000 for up to 1 year. | This will support projects investigating gambling and/or gaming in the following research areas: • risk and/or protective factors and the development of problematic gambling or gaming, including co-morbidity with substance use and/or mental health disorders; • evaluation of interventions to prevent, reduce the harms of or treat the full spectrum of problematic gambling or gaming, including interventions that consider the prevention or treatment of comorbid substance use or mental health disorders. This can include the development and evaluation of novel interventions or the evaluation of existing interventions; • evaluation of policies and regulations relating to gambling or gaming that have the potential to impact health. | Registration: September 26, 2023. Application: October 10, 2023. | |
| Tri-Agency | CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) Training and Community Support Grant (2023/2024) | Up to $50,000. | This will support INMD research communities, including researchers and Partner Organizations (i.e., voluntary health sector organizations such as non-profit organizations, professional organizations and registered charities), to build training programs in research domains largely and directly relevant to the Institute's mandate. INMD will fund one grant. The grant may be used to develop and support training curriculum, training and career development meetings and events, or mentoring activities. | September 29, 2023. | |
| Tri-Agency | CIHR Operating Grant: Canadian Research Initiative in Substance Misuse (CRISM) Indigenous Engagement Platform | One Indigenous Engagement Platform of up to $400,000 per year for up to 5 years (total $2,000,000). | This funding opportunity will support the development of an Indigenous Engagement Platform to foster and encourage distinctions-based and Indigenous-led community-based substance use research and knowledge mobilization that is founded in Indigenous ways of knowing, priorities, and values. The Platform will also provide a foundation to support existing and develop new relationships between the CRISM Network and First Nations, Inuit and Métis Peoples, including Urban Indigenous communities. | October 5, 2023. | |
| Tri-Agency | CIHR Team Grant: Strengthening the Health Workforce for System Transformation | ISTs: Up to $250,000 per year for up to 3 years; ESKM Hub: $375,000. | This funding opportunity will support research that strengthens the health workforce, which is an essential component of advancing the Quadruple Aim and health equity for health system transformation. The research will be led by teams who will inform the implementation, evaluation and/or spread/scale (share) of evidence-informed workforce solutions that address system level challenges (e.g., system organization, governance, accountability, remuneration, capacity building). Supplemental funding is available for one of the funded teams to build an Evidence Support and Knowledge Mobilization (ESKM) Hub to support the timely dissemination, exchange, and uptake of evidence into policy and practice. | Registration: October 5, 2023. Application: November 9, 2023. | |
| Tri-Agency | CIHR Catalyst Grant: Analysis of CLSA Data | Value: Up to $70,000 for up to 1 year. | The specific objective of this funding opportunity is to catalyze and support research efforts of Canadian researchers to use the available Canadian Longitudinal Study on Aging (CLSA) data in order to better understand how biological, medical, psychological, social, lifestyle and/or economic aspects of people's lives have an impact on both maintaining health and the development of disease and disability as people age. | Registration: September 19, 2023. Application: October 19, 2023 | |
| Tri-Agency | CIHR Catalyst Grant : Healthy Youth (2023) | Up to $100,000 per year for up to 1 year. | The specific objectives of this funding opportunity are to: • Support the growth of emerging research foci and priorities that have the potential to advance the health and well-being of youth in Canada; • Support the development of collaboration, both within the research community, as well as with knowledge users, policy makers and other key partners, including youth, that will enhance interdisciplinary and cross-sectoral approaches to research and knowledge mobilization; and • Build capacity, both in terms of the researcher career pathway, and the engagement of youth throughout the research process to enhance youth health research. | Registration: October 12, 2023. Application: November 8, 2023. | |
| Tri-Agency | CIHR Operating Grant: Addressing Infectious and Congenital Syphilis in Canada (Infectious and Congenital Syphilis in Canada : Implementation and Intervention Research Response) | up to $250,000 per year for up to one year. | The purpose of this funding opportunity is to address the urgent needs for implementation science and intervention research in the rapidly changing syphilis landscape. Proposed research should identify strategies and models that improve access to care and lead to more effective diagnosis and treatment, as well as reduced transmission of infectious and congenital syphilis. | Registration: October 12, 2023. Full Application: November 27, 2024. | |
| Tri-Agency | New Frontiers in Research Fund (NFRF) 2023 Exploration Competition | Value: Up to $125,000 per year (including indirect costs) for up to 2 years. | The goal of the Exploration stream is to inspire high-risk, high-reward and interdisciplinary research. Exploration grants support research that pushes boundaries into exciting new areas. Researchers are encouraged to undertake research that would defy current paradigms; brings disciplines together in unexpected ways and from bold, innovative perspectives; and has the potential to be disruptive or deliver game-changing impacts. If you plan to apply, please let us know ASAP by email to VPRI@unityhealth.to. | Notice of Intent: October 11, 2023. Please note that the NOI is not adjudicated. Full pplication: December 12, 2023. NOTE: Submissions for all stages of all NFRF competitions must be submitted by no later than 10:00AM on the day of the deadline. This internal deadline is mandatory in order for ORA to approve the submission and forward it to NFRF. | |
| Tri-Agency | CIHR Pan-Canadian Network for HIV/AIDS and STBBI Clinical Trials Research – Phase 1 | $25M for 5 years. | This seeks to support a single, nationally-coordinated, interdisciplinary clinical trials research network (the Network) for addressing STBBI, including but not limited to HIV/AIDS, hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis and human papilloma virus (HPV). The Network is expected to establish research infrastructure that facilitates the advancement of innovative, community-centred clinical trials research, including research to address STBBI in the context of co-morbidities, co-infections, and disparities in the health and well-being of key populations disproportionately affected by STBBI in Canada. | CIHR will be holding a webinar on this funding opportunity: September 27, 2023, at 2: 00 pm ET. Registration: October 25, 2023. Full Application: February 21, 2024. | |
| Tri-Agency | CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) Early Career Researcher Partnership Prize | Up to $2,500 per partner organization | This seeks to enhance health in relation to diet, digestion, excretion, and metabolism; and to address causes, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions and problems associated with hormone, digestive system, kidney, and liver function. This will support ECR Prizes awarded by Partner Organizations that recognize outstanding research relevant to the Institute's mandate. | Accepted on an ongoing basis until November 1, 2023. | |
| Tri-Agency | CIHR Operating Grant: Evaluation of Dementia Programs, Services, & Care Models | Up to $250,000 per year for up to 3 years. | This will support Implementation Science Teams to evaluate the effectiveness of equitable and inclusive solutions to improve care and services for persons with lived and living experience of cognitive impairment and dementia, including their care partners, leading to more successful integration of evidence-based practices, interventions and/or policies into routine care and public health. | Registration: November 2, 2023. Application: December 5, 2023. | |
| Tri-Agency | CIHR Team Grant: Improving Diagnosis for Rare Disease Patients | Up to $458,333 per year for up to 3 years. | This will support research that will determine the best pathway to diagnose rare diseases by moving genomic testing towards the front end of the care pathway, taking into consideration optimal integration in clinical care, ethical legal and social aspects, and resources required to support this integration. To achieve this goal, research will generate evidence that allows adequate assessment of the clinical effectiveness, economic feasibility and effects on the socioeconomic and psychological wellbeing of patients, caregivers, and family members. | November 7, 2023. | |
| Tri-Agency | CIHR Team Grant: Improving Health and Administrative Data and Monitoring for Rare Diseases | $400,000 per year over 4 years. | This will support implementation research to determine the prevalence, direct cost, and burden of rare diseases in the Canadian health care systems. This effort will enable prospective research for patients in Canada by allowing their identification in the administrative databases. It is expected that the new knowledge generated through this funding opportunity will lead to more accurate and equitable partitioning of resources (e.g., diagnosis, treatment, research, indirect support for patients and families), based on the burden of rare diseases and impact on the health care system, patients, and their families. The funded research will inform the required adaptations to the administrative coding system used in Canada to appropriately capture rare diseases data. | November 7, 2023. | |
| Tri-Agency | CIHR Operating Grant: HCRI - Data Analysis Using Existing Databases and Cohorts | Up to $100,000 for up to 1 year. | This supports research that leverages existing data to improve the health, wellness and health equity of urban populations. The goal is to use existing cohorts, data platforms and/or administrative datasets to advance healthy cities intervention research and implementation science. There are two research areas: general pool and urban Indigenous health pool. | November 11, 2023. | |
| Tri-Agency | CIHR Training Grant: Health Research Training Platform (2024/2025) | Ranges from up to $400,000 to $1,008,333 per year for up to 6 years, depending on research area. | This is intended to support the development of interdisciplinary, inter-jurisdictional, and intersectoral research training platforms that will attract a diverse cadre of trainees and early career researchers, and equip them with the foundational skills and knowledge required for a wide range of careers within and outside of academia. It will support projects relevant to the following research areas: Brain Health and Cognitive Impairment in Aging; Health System Impact Training Platform; One Health – Antimicrobial Resistance; One Health – Emerging Zoonoses; Bioinformatics, Computational Biology, and Health Data Sciences. | Registration: November 15, 2023. Application: February 1, 2024. | |
| Tri-Agency | CIHR Team Grant: Lung Health | $400,000 per year for 5 years. $750,000 per year for 5 years for the Data Science, Policy and Lung Health research area, so support infrastructure and coordination of the Data and Biosample cross-cuttting theme on behalf of all research teams supported through this funding opportunity. | This is to fund interdisciplinary teams that will address ongoing, new and emerging threats to lung health by improving the understanding of biological, social, environmental and behavioural effects on lung health. Collectively, these teams will develop and disseminate evidence-based solutions for better lung health and overall wellness, including a focus on health disparities; equity, diversity and inclusion (EDI) analyses; and Indigenous contexts. | November 16, 2023. | |
| Tri-Agency | CIHR Operating Grant: Network Environment for Indigenous Health Research Centre - Development Grant (Yukon) | Up to $75,000 for 1 year. | This development grant will provide support for development activities, including community personnel support and travel support to attend gatherings of Indigenous communities, researchers, knowledge users, stakeholders, and/or partners, in preparation of a Yukon NEIHR Centre Operating Grant application. | April 3, 2024. | |
| Tri-Agency | CIHR Pre-Announcement: National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition | It is anticipated that $9.6M will be allocated to the National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition. | The Coalition will be composed of virtual hubs across Canada linked through a coordinating centre. The hubs and the coordinating centre will work together collectively to maximize the visibility and impact of women's health research and practice in Canada by committing to the principles of equity, diversity, inclusion, and Indigenous Rights. Applications for the hubs and coordinating centre will occur through two separate funding opportunities. | Anticipated Launch: Fall 2023. | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Addressing Infectious and Congenital Syphilis in Canada | Up to $250,000 per year for up to 1 year. | This is to address the urgent needs for implementation science and intervention research in the rapidly changing syphilis landscape. Proposed research should identify strategies and models that improve access to care and lead to more effective diagnosis and treatment, as well as reduced transmission of infectious and congenital syphilis. It is envisioned that by establishing meaningful community partnerships, these intervention research and implementation science teams will also lay the foundation for future community-centred responses to health emergencies. Two research areas are anticipated: Research Area 1: Implementation Science for Syphilis Point of Care Testing; and Research Area 2: New Models of Care for Prevention of Congenital Syphilis. | Anticipated Deadlines* Registration: Late September 2023. Application: Late November 2023. *These deadlines are estimates and subject to change. | |
| Tri-Agency | CIHR Team Grant : Brain Health and Cognitive Impairment in Aging KM Hub | Strengthening Workshop: Up to $25,000; KM Hub: Up to $250,000 per year for 6 years. | The objectives of the KM Hub are to: • Accelerate and facilitate dissemination of evidence-based information through an inventory function to provide equitable and inclusive access to research findings to diverse audiences across Canada, promoting health literacy. • Contribute to the dissemination of the knowledge created by research in areas related to the National Dementia Strategy. • Foster impactful, equitable and accessible uptake of knowledge (including official language considerations) created through research, to inform policy development and/or promote implementation of evidence-based interventions. • Increase collaborations and create linkages between a diversity of researchers and knowledge users in the brain health and cognitive impairment in aging field, including partners in research (e.g., Indigenous communities), and the public. | ||
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity - Team Grants: Embracing Diversity to Achieve Precision and Increase Health Equity | LOI Stage: $20,000 Engagement Grant; Full Application: Up to $400,000 per year for up to 5 years, and $150,000 per year for 5 years for one KM Hub supplement. | This will fund new research that will improve health and achieve more equitable outcomes in nutrition, metabolic health and chronic high burden diseases, as well as sexually transmitted and blood-borne infections (STBBI), across the life course of diverse groups of people in Canada by: • Developing precision medicine approaches to characterize the variability in mechanisms of disease, prevention, detection, and to develop more effective interventions in terms of disease susceptibility, progression, resilience and reversibility, and treatment; • Increasing our understanding of interactions between structural, social, environmental, and biological determinants of health in Indigenous communities that underlie heterogeneity in health and disease; and/or • Increasing our understanding of interactions between structural, social, environmental, and biological determinants of health with particular emphasis on a diversity of populations who have historically experienced inequitable outcomes in Canada and at-risk groups that underlie heterogeneity in health and disease. | Letter of Intent: January 9, 2024. Full Application (by invitation): July 10, 2024. | |
| Tri-Agency | New Frontiers in Research Fund (NFRF): 2024 Transformation Competition | Between $2 million and $4 million per year (including indirect costs) for 6 years. | The Transformation stream supports large-scale, Canadian-led interdisciplinary research projects that address a major challenge with the potential to realize real and lasting change. The challenge may be fundamental, leading to a scientific breakthrough, or applied, with a social, economic, environmental or health impact. Projects are expected to be world-leading, drawing on global research expertise, when relevant. Transformation stream grants will support projects that: 1. tackle a well-defined problem or challenge; 2. propose a novel world-leading approach that is different from the current state-of-the-art approaches to the issue; 3. are interdisciplinary, bringing different perspectives to the defined problem; and 4. have the potential to be transformative, defined as the potential to create a significant and real change or impact—a noticeable leap or tangible breakthrough rather than an incremental advance. | Notice of Intent (NOI; Mandatory): October 24, 2023. Letter of Intent (LOI): January 10, 2024. Full Application (by invitation): September 5, 2024. | |
| Tri-Agency | NSERC Alliance Grants | $20,000 to $1 million per year for 1-5 years | Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Tri-Agency | NSERC Alliance International | Catalyst Grants: $25,000 for 1 year. Collaboration Grants: Up to $100,000 per year for up to 3 years. | These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Other Canadian | Ontario HIV Treatment Network (OHTN): HIV Endgame Funding Program | Various based on funding opportunity | • Community Based Project and Participatory Evaluation Program (CBPPEP): Provides financial support to eligible community-initiated HIV projects, needs assessments, quality improvement programs, and participatory evaluations that explore issues of importance to community-based organizations and will have a meaningful impact on those most affected by HIV in Ontario in the next 2-3 years. Value: $25,000 - $50,000 in one-time funding for up to 1 year. Deadline: October 27, 2023. • Incubator Grant: Supports projects that are deemed high-risk, high-reward and that will test, evaluate, and scale up innovative interventions and effective programs and services for the population living with HIV and at risk for HIV in Ontario. Value: $50,000 - $300,000 per year for up to 2 years. Deadlines: Letter of Intent (LOI): Every first Friday of the month; Full Application (by invitation): As per LOI notification letter. | Community Based Project and Participatory Evulation Program (CBPPEP) October 27, 2023 Incubator Grant Every first Friday of the month | |
| Other Canadian | Cystic Fibrosis Foundation (CFF): Various Opportunities | • Idea Development Award: Up to USD $150,000 per year for up to 3 years. • Biological Basis for Cystic Fibrosis-Related Diabetes Program: Up to USD $50,000 for 1 year. • CFF/NIH R01-Unfunded Award: Up to USD $125,000 per year for up to 2 years or until NIH funding is secured. | • Idea Development Award: Supports projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease. Value: Up to USD $150,000 per year for up to 3 years. Deadlines: TBA in August, 2023. • Biological Basis for Cystic Fibrosis-Related Diabetes Program: Supports work that leads to sufficient project development to enable an application for future research funding from the Cystic Fibrosis Foundation or the National Institutes of Health. Value: Up to USD $50,000 for 1 year. Deadlines: TBA in August, 2023 • CFF/NIH R01-Unfunded Award: This provides bridge funding for CF-relevant R01/R21 (or equivalent) applications that were submitted to NIH (or other governmental agencies) that scored in the 40th percentile but were not awarded by the funding agency. Value: Up to USD $125,000 per year for up to 2 years or until NIH funding is secured. Deadline: Rolling. | • Idea Development Award: TBA in August, 2023. • Biological Basis for Cystic Fibrosis-Related Diabetes Program: TBA in August, 2023 • CFF/NIH R01-Unfunded Award: Rolling. | |
| Other Canadian | Brain Canada Foundation: Congenital Heart Disease (CHD) Team Grants | Up to $350,000 per year for a maximum of 5 years. | This aims to bring together multi-institutional, interdisciplinary health research teams with multiple collaborators (e.g., researchers, clinicians, people with lived/living experience (PWLE), health care providers, Indigenous Elders or Knowledge Keepers, government, policy makers, not-for-profit organizations, and industry) to create and mobilize knowledge that will improve the health and wellness of individuals living with CHD, their families and caregivers. Research Teams will focus on one of three priority Research Areas: (1) Causes and Early Detection; (2) Brain Health & CHD; and (3) Care Transitions. | Registration: September 15, 2023. Application: November 15, 2023. | |
| Other Canadian | Ontario Research Fund-Research Excellence (ORF-RE) Program Round 12 | Stream 1: $500,000 to $2,000,000 from ORF-RE (1/3 of total funding) for a project length of up to 5 years; Stream 2: $300,000 to $2,000,000 from ORF-RE (1/3 of total funding) for a project length of up to 4 years. | Round 12 of the ORF-RE funds projects that demonstrate strong commercialization potential. There are two streams: Stream 1: Basic and Applied Research: For projects where the innovation is at a Technology Readiness Level (TRL) of 1 or 2; Stream 2: Experimental Research: For projects where the innovation is at a TRL of 3 or higher. Both Stream 1 and Stream 2 require a private sector partner. For Stream 2, at least one private sector partner must be an Ontario-based company. To be competitive for this funding you MUST have a for-profit industry partner that will provide ~1/3 of the total budget in matching (cash and in-kind) support. The VPRI Office will NOT support applications that have less than 25% of their budgeting coming from the private sector. | Please let the VPRI Office (VPRI@unityhealth.to) know ASAP if you are interested in applying for this funding. Potential applicants are strongly encouraged to attend a virtual infosession on June 27, 2023. Sponsor Deadline: September 27, 2023. | |
| Other Canadian | Brain Canada Foundation / Alzheimer’s Association: Advancing Research on Care & Outcome Measurement 3.0 (ARCOM-3) | Value: Up to USD $250,000 over up to 2 years | This is an international and collaborative competition aimed at addressing significant gaps in care and outcome measurement, and providing an opportunity to advance research so that care providers can ensure that they are implementing evidence-based practices and achieving desired outcomes. Areas of interest for this program include, but are not limited to, quality metrics, systems of care, translation of interventions, increasing diversity within research and clinical trials, risk reduction, development of novel methods of data collection or analysis, and novel measures to validate previously developed measures or evaluation of measures in diverse and underrepresented populations. | Letters of Intent: September 20, 2023. Full Applications: November 29, 2023. | |
| Other Canadian | Keenan PDF Scholarship | The scholarships provide $50,000 for one year of funding to be put towards the salary of a PDF. | The Keenan Post-Doctoral Scholarship Program was established to support research conducted at Unity Health Toronto (Unity Health), by enabling the recruitment and retention of top-quality post-doctoral fellows (PDFs). The scholarships provide $50,000 for one year of funding to be put towards the salary of a PDF. Applications have been emailed to all appointed researchers, any individuals wishing to apply can email VPRI@unityhealth.to to get a copy of the application. | The applications are due by Tuesday September 26th, 2023 to VPRI@unityhealth.to. | |
| Other Canadian | Brain Canada Foundation / Brain Changes Initiative: Innovation Grants for Research Impact in Traumatic Brain Injury | Not specified. Term is for 2 years. | This is intended to generate creative, novel and practical evidence-based solutions that address stakeholder-identified and prioritized needs to improve the trajectory of recovery for individuals after brain injury. The prioritized needs are: • Full assessment and customized treatment plan informed by the areas of brain that were damaged and severity • Less emphasis on structural characteristics and more on functional ability during assessments • Reduced waiting lists/immediate access to outpatient brain injury services and treatment facilities • Transfer of information from emergency departments to family physicians so brain injury is not missed • Ongoing education (CMEs) for doctors about new research and therapies for brain injury • Accurate prognostication (to know expected outcomes) to inform decision-making by doctors, families, and insurance payees • Reduced bureaucracy, paperwork, unnecessary delays, and barriers across systems (health, financial, insurance, legal, etc.) • Minimize occurrence of incorrect assumptions that can prevent detection of brain injury, especially for Indigenous Peoples • Increased detection, treatment, and prevention for special populations (e.g., people in situations of abuse, people experiencing homelessness) This funding opportunity is open to interdisciplinary research teams of two or more members and must include a minimum of two independent investigators. | Registration: September 27, 2023. Full Application: January 25, 2024. | |
| Other Canadian | Lung Cancer Canada: Geoffrey Ogram Memorial Research Grant | Up to two grants of $25,000 CAD each will be awarded. | The goal of this program is to provide a mechanism for scientists to study innovations and accelerate the application of new knowledge relating to the early detection of lung cancer and the etiology of lung cancer in different demographics and populations. Applications are encouraged from, but not limited to, the areas of biomedical, clinical, health services, social, and population health research. | September 30, 2023. | |
| Other Canadian | U of T Temerty Faculty of Medicine: Temerty Ukraine-Toronto Education and Collaboration Fund | Up to $75,000 for up to 2 years. | This is to support health leaders in Ukraine and the U of T’s Temerty Faculty of Medicine in Canada through collaborative research and educational programs, initiatives and activities. Specific attention will be given to applications that address: orthopedic care, development of administrative skills in healthcare systems, and collaboration with the National University of Kyiv-Mohyla Academy. | September 30, 2023. | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Various Opportunities | • Leveraging Grants: Up to $80,000. • Team Development Grants: Up to $10,000 for up to 18 months. • Small Grants: Up to $10,000 for up to 1 year. | • Leveraging Grants: To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. • Team Development Grants: To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs. • Small Grants: To support small developmental initiatives typically intended to lead to major grant applications. NOTE: For AGRI grants, the applicant must be one of the principal investigators and have grant-holding status at the University of Alberta, Calgary, or Lethbridge. Research collaborators may come from other institutions. | • Leveraging Grants: Rolling call. • Team Development Grants: Rolling call. • Small Grants: October 1st and May 1st each year. | |
| Other Canadian | Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER): Dr. David L. Epstein Award | USD $100,000 for 1 or 2 years. | Open to ARVO members who are well-established, senior-level investigators with documented history of conducting eye and vision research in glaucoma and who have a record of successfully mentoring clinician-scientists to independent academic and research careers. The award will fund a research project that supports the applicant’s mentee in the applicant’s lab. Please see the funding opportunity website for additional eligibility criteria. | October 1, 2023. | |
| Other Canadian | Kidney Foundation of Canada (KFOC): Kidney Health Research Grants | $180,000 for 3 years. | The KFOC encourages and supports research across the four pillars (biomedical, clinical, health systems, & population health) to improve treatments and quality of life for people with kidney disease. | Letter of Intent: October 2, 2023. Full Application: November 13, 2023. | |
| Other Canadian | Government of Canada Innovation, Science and Economic Development Canada (ISED): Innovative Solutions Canada Program Testing Stream (ISC TS) | Standard component: $1,150,000; Military component: $2,300,000. 12 month contract period. | ISC TS is a R&D program aimed at procuring, testing and evaluating R&D, pre-commercialized goods and services in the late stage development [Technology Readiness Level (TRL) 7 to 9]. It aims to procure, test and evaluate innovative late stage pre-commercial prototypes The purpose is to create pools of conditionally qualified innovations that Canada may select from to address a broad range of the Government of Canada organizations' requirements. This seeks pre-commercial innovative prototypes that can be tested in real life settings in the following areas: Health and Disease Prevention; Advanced and Emerging Medical Technologies. Please see solicitation for more details. | October 3, 2023. | |
| Other Canadian | Multiple Sclerosis Society of Canada: Discovery Research Grants | $50,000-$100,000 per year for up to 3 years. | This will support support various research projects aligned with the MS Canada’s new strategic plan. The strategic plan outlines four key impact areas: Advance Treatment and Care, Enhance Well-being, Understand and Halt Disease Progression, and Prevent MS. | October 3, 2023. | |
| Other Canadian | Multiple Sclerosis Society of Canada (MSSC): Various Opportunities | Various based on funding opportunity | • Discovery Research Grants: This supports research projects aligned with the MSSC’s strategic plan. Applicants can apply to either the Biomedical Research Stream or the Clinical and Population Health Research Stream. Value: Between $50,000 - $100,000 per year for up to 3 years. • Catalyst Research Grant: This awards seed funding that allows researchers to develop and test new and innovative research questions and pursue pioneering approaches that have high potential to advance the MS field. Proposals should address research questions in one or more of the impact goal areas identified in the MSSC strategic plan. Applicants can apply to either the Biomedical Research Stream or the Clinical and Population Health Research Stream. Value: Up to $50,000 for up to 2 years. | October 3, 2023. | |
| Other Canadian | Mitochondrial Innovation Initiative (MITO2i) Graduate Student Scholarship Awards | Up to $10,000 for one year. | This provides funding support to highly accomplished graduate student candidates who demonstrate outstanding potential to become independent researchers in Mitochondrial Research and Medicine. All Graduate Students in any year of their studies can apply from U of T and any of the partnering hospital institutions participating in the call for proposals, including Unity Health. | October 6, 2023. | |
| Other Canadian | Hold’em for Life Oncology Fellowship | $50,000 for salary support. | These fellowships are open to University of Toronto residents and clinical fellows pursuing cancer research, at any of the Faculty’s nine fully affiliated teaching hospitals. A multidisciplinary U of T committee will annually review and rate all proposals. | October 6, 2023. | |
| Other Canadian | U of T Data Sciences Institute (DSI) Research Software Development Support: Call for Projects | Up to a 0.5 FTE research software developer for 2 to 6 months. | This is to help researchers to refine existing software tools to improve usability and robustness or build new tools, disseminate research software beyond the research space in which it is created, and to enhance existing functionality. It provides research groups access to a professional research software developer. Only open-source projects are considered for support. | October 20, 2023. | |
| Other Canadian | Canadian Institute for Advanced Research (CIFAR): Azrieli Global Scholars | $100,000 for 2 years. | CIFAR invites outstanding early-career researchers from across the natural, biomedical, life and social sciences and the humanities to join one of their interdisciplinary research programs that address some of the most important questions facing science and humanity. The program is designed to accelerate the development of early-career researchers in their pivotal first years as independent principal investigators in an academic or research institution, with responsibilities for research and teaching. | October 30, 2023. | |
| Other Canadian | Canadian Orthopaedic Foundation: Canadian Shoulder and Elbow Society (CSES) Research Grant | Up to $20,000 for 1-2 years. | This is to support and encourage orthopaedic surgeons to conduct collaborative shoulder or elbow research. One of the principal investigators must be a member of CSES in good standing. One of the principal investigators must be an orthopaedic surgeon working in a Canadian orthopaedic centre both at the time of application and at the award’s receipt. One of the Principal or Secondary Investigators must be a COA member or associate member in good standing. The project should propose a pre-clinical or clinical study with the potential to improve clinical outcomes of a shoulder or elbow disorder | October 31, 2023. | |
| Other Canadian | Orthopaedic Research Society (ORS)/Orthoregeneration Network (ON): ON/ORS Kick-Starter Grants | USD $10,000. | These grants support research that focuses on an innovative approach in regenerative orthopaedics or that answers an important open question in that field. The topic is innovative techniques and materials for the regeneration of musculoskeletal tissues. Candidates must be ORS members at the time of application and have not benefited from an ON/ORS support program before. | November 1, 2023. | |
| Other Canadian | Canadian Blood Services (CBS): BloodTechNet Award Program | Up to $50,000 for up to 1 year. | This is to facilitate the development of innovative educational projects in the transfusion, cellular therapy and transplantation communities in Canada. It supports projects delivering educational tools and resources that support the development of skills, knowledge and expertise of health professionals in these communities. The BloodTechNet Award Program is targeted towards medical lab technologists, nurses and physicians. | November 15, 2023. | |
| Other Canadian | U of T Data Sciences Institute (DSI) 2024 Summer Undergraduate Data Sciences (SUDS) Program | $7,200 provided by the DSI to the supervisor for the student’s stipend for 12 full weeks. | SUDS research opportunities are being solicited from UofT faculty members and DSI funding partner scientists that are focused on data sciences methodology or applications in any research area. Research opportunities can include any aspect of basic, applied, or clinical research. Unity Health scientists are eligible to apply. | November 15, 2023. | |
| Other Canadian | Mitacs Globalink Resarch Award | $6,000 for a 12- to 24-week research project for a trainee jointly supervised by a home and host professor at a university in Canada and an institution affiliated with one of Mitacs’s international partners. | This is a competitive call for applications in all areas of strategic importance for the Canadian and international research communities. Professors can submit projects in the themes, which include, but are not limited to, the list below. There is a great deal of scope under the open theme social and scientific innovation: 1) Advanced computing (e.g., AI and Quantum technologies, Robotics, Cybersecurity) 2) Clean technologies (e.g., electric vehicles) 3) Health Innovations (e.g., biomanufacturing) 4) Open theme: Social and scientific innovation | November 17, 2023. | |
| Other Canadian | Sigma Theta Tau International Honor Society of Nursing (STTI) / Canadian Nurses Foundation (CNF) Grant | Up to USD $5,000. | This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. | December 1, 2023. | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 to pay for CRO services for up to a 1 year term. | This will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. | Open competition with no set deadline. | |
| Other Canadian | Grand Challenges Canada: Transition To Scale (TTS) Request for Proposals | Range from $250,000 to $3M for 6 months up to 2 years | This seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. It supports promising innovations with a proven impact that have the potential to save or improve lives. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. Applicants must be either a non-profit organization, for-profit company, research/academic institution, or another recognized institution that is incorporated in a low- or middle- income country, with a current priority in Sub-Saharan Africa | Concept notes accepted on a rolling basis | |
| Other Canadian | University of Toronto Institutional Strategic Initiatives (ISI) | From $50,000-$300,000 per year for up to 3 years. | ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding. | Ongoing | |
| Other Canadian | Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs | -- | The NRC offers potential opportunities for collaboration in the following areas: • Aging in Place • Artificial Intelligence for Design • Disruptive Technology Solutions for Cell and Gene Therapy • High-throughput and Secure Networks • Pandemic Response Potential collaborators can register their interest to work with NRC on the Challenge Programs website. | Ongoing | |
| Other Canadian | Rare Diseases: Models & Mechanisms Network Catalyst Grants | $25,000 | The Rare Diseases: Models & Mechanisms Network has been established to catalyze connections between people discovering new genes in patients with rare diseases, and basic scientists who can analyze equivalent genes and pathways in model organisms. Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher. | Continuous. | |
| Other Canadian | Government of Canada: CanExport for Innovators | Maximum of $75,000 | Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration. Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities. | Continuous | |
| Other Canadian | Weston Brain Institute: Early Phase Clinical Trials: Canada | Up to $1,500,000 per project for up to 4 years | Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data. | Rolling deadline | |
| Other Canadian | Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant | Health Research Grant: Up to $250,000 for 3 years. New Investigator Grant: Up to $300,000 for 3 years. | Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. | Rolling deadline | |
| Other Canadian | Telus Funds | Various | For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition. | Various | |
| Other Canadian | Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program | Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.) | This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion). If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to). | No Deadline | |
| International | Biogen: Various Opportunities | -- | Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas: • Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited. • Patient Education: Supports independent educational activities for patients or caregivers. • General Grant: Supports a project or program that does not fit any of the other defined grant categories. | April 15, August 15, November 1. | |
| International | Gateway for Cancer Research: GFCR Integrative Program | Up to USD $1.5M for a maximum of 2.5 years. | This supports Phase I and II patient-centered cancer clinical trials focusing on the following priority research areas: Biomarkers/Molecular Markers; Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. The focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Mediciane; and Integrative Medicine. | Letter of Intent Deadlines: August 31, 2023; November 1, 2023; January 31, 2024; May 2, 2024. | |
| International | International Center for Responsible Gaming (ICRG) 2023 Grants Program | Various values depending on opportunity | • REQUEST FOR APPLICATIONS FOR RESEARCH ON ONLINE GAMBLING: Researchers are invited to apply for a Large Grant to study online gambling in the U.S. Value: Up to USD $172,500 for up to 2 years. Deadline: September 29, 2023. • REQUEST FOR APPLICATIONS FOR RESEARCH ON RESPONSIBLE GAMBLING AND PREVENTION: Researchers are invited to apply for support of research on responsible gambling and prevention strategies to reduce gambling-related harms. The safety and effectiveness of Voluntary Self-Exclusion is a priority but other topics in this area are also welcome. Value: Up to USD $207,000 for up to 3 years. Deadline: October 16, 2023. | REQUEST FOR APPLICATIONS FOR RESEARCH ON ONLINE GAMBLING: September 20,2023 REQUEST FOR APPLICATIONS FOR RESEARCH ON RESPONSIBLE GAMBLING AND PREVENTION: October 16, 2023 | |
| International | American Academy of Neurology (AAN) Career Development Award (CDA) | USD $150,000 per year for 3 years. | Supports junior investigators interested in an academic career in neurology. Recipient must be a neurologist and an AAN member interested in an academic career in neurologic research who completed residency between 5-10 years prior to the start date of the Career Development Award (July 1, 2024). | September 14, 2023. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Kidney Cancer Research Program (KCRP): Various Opportunities | Range from up to USD $100,000 to USD $6M for up to 1 to 4 years, based on funding opportunity type. | • Academy of Kidney Cancer Scholars Early-Career Investigator Award: Applicant must be within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. Preliminary data required. Value: Up to USD $750,000 for up to 4 years. • Clinical Trial Award: Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase 1, pilot Phase 2) to test interventions that will have a major impact in the field of kidney cancer. Value: Up to USD $1.5M for up to 4 years. • Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved outcomes. Preliminary data are required. Value: Up to USD $800,000 for up to 4 years; Partnering PI Option: Up to USD $1,200,000 for up to 4 years. • Clinical Consortium Award: Supports a consortium to facilitate the rapid execution of collaborative phase 1 and 2 clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer. Value: Coordinating Center: Up to USD $6,000,000 for up to 4 years; Clinical Research Site: Up to USD $800,000 for up to 4 years. • Nurse-Initiated Research Award: Supports nursing research pertaining to kidney cancer patient care. An eligible PI must be a licensed registered nurse with a terminal degree of a Doctor of Nursing Practice (D.N.P). and/or Ph.D. (or equivalent). Value: Up to $195,000 for up to 3 years. • Translational Research Partnership Award: Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. Value: Up to USD $750,000 for up to 3 years. | Pre-Application (Preproposal): September 15, 2023 Application: October 6, 2023 | |
| International | SONY Research Award Program: Various Opportunities | Values based on opportunities | • Faculty Innovation Award: This provides funds to conduct pioneering research in the following areas: Information Technology, Devices and Materials, and Biomedical and Life Science. Value: Up to USD $100,000. • Focussed Research Award: This provides an opportunity for university faculty, research institutes, and Sony to conduct collaborative, focused research. Focus research themes can be found here. Value: Up to USD $150,000. | September 15, 2023 | |
| International | Orphan Disease Center: Million Dollar Bike Ride Pilot Grant Program | This provides a one‐year grant to support research related to a rare disease represented in the 2023 Million Dollar Bike Ride. Research focus areas for pilot grants can be found here. | Expression of interest: September 15, 2023 Full Proposal: October 16, 2023 | ||
| International | ICRG: REQUEST FOR APPLICATIONS RESEARCH ON GAMBLING ADVERTISING CALL RE-OPENED | $75,000 per year of up to 2 years plus 15% in facilities & administration costs (total amount that may be requested is $172,500). | The ICRG invites investigators to apply for a two-year Large Grant to study the impact of gambling advertising, including television, digital and push notifications. The goal of this initiative is to determine the aspects of advertising that might promote risky or problematic gambling attitudes and behaviors and provide metrics for the development of advertising guidelines for gambling operators and regulators. | September 15, 2023. | |
| International | Thoracic Surgery Foundation (TSF): Various Opportunities | Values based on opportunities | • TSF Research Award: This grant is for cardiothoracic surgeons who have completed their formal training and are seeking initial support and recognition for their original research project. The applicant must be a cardiothoracic surgeon who has completed a program leading to certification by the American Board of Thoracic Surgery or its equivalent in a country outside of the United States, or who will be certified by the grant start date (July 1, 2024), and who is within seven years of their first faculty appointment. Value: USD $85,000 per year for 2 years. • STS Research Award: This will be given to the highest-ranking TSF research application awarded by TSF based on merit as judged by a rigorous peer review process. Value: USD $90,000 per year for 2 years. • AstraZeneca/TSF Lung Cancer Research Award: This provides support to investigators conducting research related to lung cancer. Applicants proposed projects should aim to reduce the burden of lung disease through the advancement of clinical, transitional and/or basic scientific research. Value: USD $50,000 per year for 2 years. • TSF AstraZeneca Reversing Health Disparities in Lung Cancer Research Award: This supports investigators conducting health disparity research related to lung cancer. Value: USD $50,000 per year for 2 years. | September 15, 2023. | |
| International | International Center for Responsible Gaming (ICRG): Various Opportunities | • Impact of Gambling Advertising: Up to USD $75,000 per year for up to for 2 years. | • Impact of Gambling Advertising: The goal of this initiative is to determine the aspects of advertising that might promote risky or problematic gambling attitudes and behaviors and provide metrics for the development of advertising guidelines for gambling operators and regulators. | • Impact of Gambling Advertising: September 15, 2023. | |
| International | American Foundation for Suicide Prevention (AFSP): Grant Cycle 2023 | Value based on funding opportunity | • Linked Standard Research Innovation Grants: For research involving two or more unique sites with each site contributing unique expertise, as well as data collection. Value: Up to USD $450,000 over 2 years. Deadlines: Letter of Intent: September 15, 2023; Full Application (by invitation): November 15, 2023. • Distinguished Investigator Innovation Grants: For investigators at the level of associate professor or higher with an established record of research and publication on suicide. Value: Up to USD $150,000 over 2 years. Deadline: November 15, 2023. • Standard Research Innovation Grants: Grants awarded to individual investigators at any level. Value: Up to USD $125,000 over 2 years. Deadline: November 15, 2023. • Early Career Researcher Innovation Grants: Grants awarded to investigators at or below the level of assistant professor. Value: Up to USD $140,000 over 2 years. Deadline: November 15, 2023. • Pilot Innovation Grants: These provide seed funding for new projects that have the potential to lead to larger investigations. These grants typically entail feasibility studies rather than hypothesis-driven research. Value: Up to USD $50,000 over 2 years. Deadline: November 15, 2023. | Various deadlines based on opportunity | |
| International | Melanoma Research Alliance (MRA) Special Opportunity - Brain Metastasis: Tara Miller Melanoma Foundation-MRA Team Science Award in Melanoma Brain Metastases Research | Up to USD $300,000 per year for 3 years. | This will support research that addresses melanoma brain metastasis. Proposals can include, but are not limited to: • Improvement of current treatment strategies, especially for patients with symptomatic brain metastases. • New approaches for inclusion of patients with melanoma brain metastases in clinical trials, incorporating asymptomatic and symptomatic patients in trial design, operational aspects and accrual, as well as the sharing of data and resources. • Examination of the origins and progression of melanoma brain metastases and the ability to prevent brain metastases. • Understanding what activates tumor cell dormancy in the brain. • Identifying the important cell types in the brain tumor microenvironment that promote tumor growth. • Identifying drugs and combinations that improve drug delivery across the blood brain barrier. • Development of new models for the study of metastasis including testing and validation of therapies. • Molecular analysis of brain metastases using state of the art technologies. | Letter of Intent: September 20, 2023. Full Proposal (by invitation): January 4, 2024. | |
| International | Oncology Nursing Society (ONS) Foundation Research Grants | USD $50,000 over 2 years | This is to support rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to current funded projects, or developing a new aspect of a program of research. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically based oncology practice. It is intended for is intended for emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of $50,000 as the study principal investigator (PI). | Letters of Intent: September 20, 2023. Full Proposals: October 31, 2023. | |
| International | Advanced Research Projects Agency for Health (ARPA-H): Precision Surgical Interventions (PSI) Broad Agency Announcement | This program aims to develop solutions to two major surgical problems: tumor edge visualization and critical anatomy visualization. PSI seeks to develop technologies that will be used by surgeons during operations to visualize tumors’ edges, in order to increase chances of complete removal. It also seeks to develop devices that surgeons can use to clearly see critical anatomy in 3D while operating. | Abstract submission: September 21, 2023 Full Proposal (by invitation only): November 16, 2023 | ||
| International | John Simon Guggenheim Memorial Foundation: 2024 Guggenheim Fellowships | Amounts of grants vary, and the Foundation does not guarantee it will fully fund any project. | These are intended for individuals who have already demonstrated exceptional capacity for productive scholarship, and exhibit great promise for their future endeavours. The unrestricted grant funds are awarded in support of a single project with a balanced, focused goal, and provide Fellows the ability to work with as much creative freedom as possible. Eligible candidates are writers, scholars, or scientists who have a significant record of publication. All applicants must be citizens or permanent residents of the U.S. or Canada at the time of application. | September 21, 2023. | |
| International | Cystic Fibrosis Foundation (CFF): Clinical Research Award | Up to USD $150,000/year for 3 years for single-center clinical research awards; Up to $350,000/year for 3 years for multi-center clinical research | This seeks investigator-initiated clinical research projects that have the potential to make an important contribution to the CFF’s mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis using clinical (observational/interventional), translational, or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls. | Letter of Intent: September 21, 2023; April 4, 2024. Full Application: August 13, 2024; February 13, 2024. | |
| International | Society of American Gastrointestinal Endoscopic Surgeons (SAGES): Various Opportunities | Between USD $20,000 to $50,000 for 1 or 2 years. | • Research Grant: Purpose is to stimulate original research in gastrointestinal and endoscopic surgery. The study may be either “bench” research or clinical. Value: Up to USD $30,000 for 1 year. • Robotic Surgery Research Grants: The purpose of these grants is to stimulate original research in robotic surgery. SAGES is interested in reviewing grants focusing on the use of robotic surgery for procedures other than colorectal surgical procedures. Value: Up to USD $50,000 for up to 2 years. • Disparities in Healthcare Grant: Prioritizes grants or quality improvement projects to potentially reduce disparities in access to MIS and robotic surgery that could be adopted more widely to address this healthcare need. Value: Up to USD $20,000 for 1 year. The SAGES research awards are open to any PI who is a current SAGES member, including candidate members. SAGES considers a young investigator as someone who has not practiced surgery independently for more than 5 years. | September 22, 2023. | |
| International | Leukemia & Lymphoma Society (LLS): Various Opportunities | Up to USD $750,000 for 3 years | • Blood Cancer Discoveries Grant Program: This program is designed to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets • Translational Research Program: This seeks applications that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. | Discoveries Grant Program: Letter of Intent: September 29, 2023, Full Proposal: March 4, 2024. Translational Research Program: Letter of Intent: October 20, 2023, Full Proposal: January 19, 2024. | |
| International | The ZOLL Foundation: Seed Grants | Typically in the USD $10,000-$50,000 range. | This invites studies in the fields of resuscitation or acute critical care that aim to improve practices, prevent patient deterioration, reduce mortality and morbidity, or address some other aspect of enhancing care. Grant applicants should be newer researchers, ideally recommended by a more established investigator. | March 31, 2023; September 30, 2023. | |
| International | Association for Research in Vision and Ophthalmology (ARVO): Various Opportunities | USD $100,000 for 2 years. | Dr. David L. Epstein Award: For well-conceived and executed scientific research focused on finding the causes and new treatments for glaucoma. The award will fund a research project that supports the applicant’s mentee in the applicant’s lab. Value: USD $100,000 for 2 years. • Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists: Research funding for early-career underrepresented minority investigators who have received their initial faculty appointment and are working to establish an independent vision research program. | October 1, 2023. | |
| International | Pfizer Global Medical Grants (GMG) Research Request for Proposals (RFP): Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada - Wave 2 Funding Round | Up to $100,000. | This seeks to support research in Canada that advances medical knowledge in the understanding, diagnosis and treatment of ATTR Amyloidosis. See Area of Interest section of RFP for further details. | October 2, 2023. | |
| International | Focused Ultrasound and ALS Research | Preclinical research projects (USD $150,000-$200,000 for 1-2 years); Clinical research projects (USD $300,000 - $600,000 USD for 1-3 years). | The Focused Ultrasound Foundation and The ALS Association established a partnership funding program earlier this year with the goal of advancing the development of new focused ultrasound applications for the treatment and diagnosis of amyotrophic lateral sclerosis (ALS). | Letter of Intent: October 2, 2023. Full Application: December 1, 2023. | |
| International | Patient-Centered Outcomes Research Institute (PCORI): Optimizing physical and mental functioning across the ageing continuum | Up to $12 million USD for up to 5 years. | PCORI aims to fund high-quality, comparative clinical effectiveness research (CER) projects that focus on optimizing physical and mental functioning for community-dwelling older adults and their caregivers. | Letter of Intent: October 3, 2023. Full Application: January 9, 2024. | |
| International | Patient-Centered Outcomes Research Institute (PCORI): Improving Methods for Conducting Patient-Centered Outcomes Research | USD $750,000 for up to 3 years. | PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and clinical comparative effectiveness research (CER). PCORI has identified the following areas as programmatic priorities: • Methods to Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Clinical Research • Methods to Improve Study Design • Methods to Support Data Research Networks • Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER | Letter of Intent: May 31, 2023; October 4, 2023; February 7, 2024. Full Application (by invitation): August 29, 2023; January 10, 2024; May 2, 2024. | |
| International | International Brain Research Organization (IBRO) Rising Stars Awards | TBD. 80% of the grant will be awarded in advance, and the remaining 20% upon completion and submission of the associated grant report | This program aims to increase the successful transition and retention of diverse, early career neuroscientists into academic positions by providing funds to make a significant difference in their research endeavors. It supports the research needs of early career faculty from diverse and/or underrepresented backgrounds (racial/ethnic minorities, sexual orientation, disability, etc) and early career faculty who do not have substantial start-up funds or grant support from other agencies. Applicants should be within the first five years of their initial faculty appointment. Preference will be given to those who have not previously received, nor expect to receive, substantial support from other sources. | October 11, 2023. | |
| International | Foundation Fighting Blindness (FFB): Program Project Award (PPA) | Up to USD $500,000 per year up to 5 years. | This award engages cross-disciplinary investigators to drive collaborative retinal degenerative disease research efforts. It enables studies that are too large or technically complex for a single investigator to undertake in a reasonable amount of time and to address current knowledge and/or therapeutic gaps. It address knowledge gaps or therapeutic goals identified by The Foundation or an equally significant gap or goal approved by the Foundation. | Letter of Intent: October 12, 2023. Application (by invitation): February 27, 2024. | |
| International | Conquer Cancer Foundation / American Society of Clinical Oncology (ASCO): Career Development Award (CDA) | USD $200,000 for 3 years. | This provides research funding to clinical investigators, who have received their initial faculty appointment. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. The applicant must be a physician and be in the first to fourth year of a full-time primary faculty appointment in a clinical department at an academic medical institution. | October 19, 2023. | |
| International | Cancer Research Institute: Technology Impact Award | Up to USD $200,000 for 1-2 years. | These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies. | Letter of Intent: November 15, 2023. Full Proposal (by invitation only): March 15, 2024. | |
| International | Cancer Research Institute (CRI): Clinical Innovator Grant | Up to USD $1M for each clinical trial | This opportunity will support for clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility, and clinical impact. Competitive applications will have a strong focus on yielding mechanistic insights into clinical response and potentials for biomarker discovery and/or validation. | Initial Protocol Concept: December 1, 2023. Full Application: May 1, 2024. | |
| International | CRI: Clinic and Laboratory Integration Program (CLIP) Grants | up to USD $150,000 per year for two years | This seeks to supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CRI CLIP Grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. | Letter of Intent: December 1, 2023. Full Application: March 1, 2024. | |
| International | Paralyzed Veterans of America (PVA) Education Foundation Grants | : Ranges between up to USD $10,000 to USD $75,000, depending on the topic category. All grants are for 12 months. | This funds educational projects that benefit and serve individuals with SCI/D, their families and caregivers. There are six topic categories for funding consideration, which are: Consumer, Caregiver, and Community Education; Professional Development and Education; Research Utilization and Dissemination; Assistive Technology; Consumer Guides; and Conferences and Symposia. | December 1, 2023. | |
| International | American Association for the Study of Liver Diseases (AASLD) – Various Opportunities | Various values depending on opportunity | • Bridge Award: This supports investigators who have recently submitted an NIH R or other federally funded equivalent award and have received competitive scores on their proposal, but were not funded. Applicants must be at or below the rank of Associate Professor. Value: USD $100,000 for 1 year. Deadline: October 5, 2023, January 15, 2024. • Pinnacle Research Award in Liver Diseases: This is a basic science award that is intended to develop the potential of outstanding, young scientists and encourage research in liver physiology and disease. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $300,000 over 3 years ($100,000 per year). Deadline: December 4, 2023. • Clinical, Translational and Outcomes Research Award: This award is intended to foster career development for individuals performing clinical research, translational research, or outcomes research in a liver-related area and who have shown commitment to excellence at an early stage of their research study. Applications in health disparities-related research are encouraged. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $200,000 over 2 years ($100,000 per year). NOTE: Up to two applications per distinct department will now be accepted per single sponsoring institution. Deadline: December 4, 2023. • Pilot Research Award in Liver Diseases: This supports highly innovative research ideas that have a clear potential to produce high-impact results, but that have little or no preliminary data. Applicants must be faculty 3 years post appointment to at or below the Associate Professor Level. Value: USD $50,000 for 1 year. Deadline: December 4, 2023. • Autoimmune Liver Diseases Pilot Research Award: This provides supplementary funding during the pilot phase of basic, translational or clinical research projects in autoimmune liver disease (e.g. autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis) in preparation for future grant applications by the recipient. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $20,000 for 1 year. Deadline: December 4, 2023. | December 4, 2023. | |
| International | American College of Gastroenterology (ACG): Various Opportunities | Various values depending on opportunity | • Junior Faculty Development Award: For junior investigators <7 years out of fellowship working toward independent careers in clinical research related to gastroenterology or hepatology who hold full-time faculty positions and have 50% protected time. Must be an ACG Member at time of application. Value: USD $150,000 per year for 3 years. • Established Investigator Bridge Funding Award: Provides support for established investigators with bridge funding for clinical research related to gastroenterology or hepatology. Must be an ACG Member at time of application and complete the Pre-qualification application by November 6, 2023. Value: USD $150,000 per year for 2 years. • Health Equity Research Award: Research to produce actionable science that will translate to reducing health and/or healthcare disparities thereby promoting health equity. Pilot data required. Must be an ACG Member. Value: Up to USD $75,000 for up to 2 years. • ACG/ASGE Epidemiologic Research Award in Gastrointestinal Endoscopy: For projects involving the use and outcomes of gastrointestinal (GI) endoscopy using the GI Quality Improvement Consortium (GIQuIC). Must be an ACG or ASGE Member at the time of application and submit a request for letter of support fro GIQuIC by November 6, 2023. Value: USD $50,000 for 1 or 2 years. • Clinical Research Award: Supports innovative patient-oriented research with direct applicability to clinical care. Pilot data required. Must be an ACG Member at the time of application. Value: Up to USD $50,000 for up to 1 year. • Clinical Research Award Pilot Projects: Supports innovative patient-oriented research and encourage clinical research among trainees and junior faculty. No pilot data is required. Must be an ACG Member at the time of application. Value: Up to USD $15,000 for 1 year. | December 4, 2023. | |
| International | GFCR Decentralized (DCTI) Grant Program | -- | This will fund research that leverages site-less, technology-informed trials was launched, with the objective of bringing clinical trials directly to patients’ doorsteps | December 15, 2023. | |
| International | GFCR Integrative Program | USD $200,000-$1.5 M for 2-5 years. | This will fund integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. | December 15, 2023. | |
| International | SIO Integrative Program | USD $200,000-$1.5 M for 2-5 years. | This seeks to fund integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. | December 15, 2023. | |
| International | GFCR Grant Program | USD $200,000-$1.5 M for 2-5 years | These core grants fund early phase clinical trials for cancers of all types at renowned institutions around the world | December 15, 2023. | |
| International | Coalition for Epidemic Preparedness Innovations (CEPI): Vaccine manufacturability focused on speed | USD 25 million for up to 3 years | This supports proposals for manufacturability-related innovations and technologies that can accelerate the time required to make clinical trial material or CTM for emergency use, in response to a new pathogen outbreak. The call is divided into four focus areas: • Focus Area 1: Platform process development in batch or continuous manufacturing mode, process optimization, standardization, and acceleration (such as mRNA, viral vectors, proteins, or other novel platforms are considered). • Focus Area 2: Analytical technologies that can accelerate drug substance/product batch release and availability of master cell bank (MCB)/ master viral stock (MVS). • Focus Area 3: Innovations to accelerate cell-based manufacturing steps, including synthetic approaches (such as the use of synthetic DNA (deoxyribonucleic acid) for mRNA manufacture). • Focus Area 4: Any other manufacturing-related innovations that can accelerate CTM availability. The use of Artificial Intelligence (AI) in developing and controlling the manufacturing process can aid in post-approval rapid vaccine deployment. | December 15, 2023. | |
| International | Linda and Les Vinney scholar programme | $100,000 guaranteed (base award) for one year; potential to qualify for additional up to $50,000 project acceleration support | This opportunity will provide funding and drug development support to researchers whose work aims to treat or prevent Alzheimer's disease. Each year up to three Vinney Scholars are chosen. | December 29, 2023. | |
| International | American Sleep Medicine Foundation (ASMF): Strategic Research Grant | USD $50,000 to $250,000 for up to 3 years. | This grant is investigator-initiated and supports high-impact research projects aimed at addressing gaps in knowledge that impact the ability to provide optimal, patient-centered, cost-effective diagnosis and care for people with sleep disorders. | Letter of Intent: October 23, 2023. Full Application (by invitation): March 11, 2024. | |
| International | American Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research Grant | USD $20,000 for 1 year. | This is for a specific project building upon psychoanalytic principles or directly investigating the process and/or outcome of psychoanalytically informed treatments. The Fund conceives of psychoanalytic research along the broadest lines, including: scholarly and empirical investigative contributions that can advance knowledge of psychoanalytic theory, practice, and links between psychoanalysis and neighboring disciplines such as developmental psychology or neuroscience. | May 1 and December 31 of each year. | |
| International | Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery | Up to USD $75,000 per project. | These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes. Principal Investigators are encouraged - although not required - to submit proposals that fall into one or more of the key research areas of interest listed on the Clinical Research Grants for Robotic-assisted Surgery website. | Letter of Intent: January 5, 2024. Full Proposal (by invitation): April 5, 2024. | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY23 Chronic Pain Management Research Program (CPMRP): Various Opportunities | Value based on funding opportunity | • Clinical Exploration Award: Supports early-phase, proof-of-principle clinical trials and correlative studies, particularly those including complementary and integrative health methods. Value: Up to USD $250,000 for up to 2 years. • Investigator-Initiated Research Award: Emphasis on innovative and impactful research. Must include preliminary and/or published data or clinical observations that originated from the research team that support the rationale for the proposed study. Clinical trials are not allowed. Value: Up to USD $900,000 for up to 4 years. • Clinical Outcomes Research Award: Supports studies designed to improve clinical outcomes through acceleration of evidence-based ideas in chronic pain management into clinical applications (e.g., health care products, technologies, practice guidelines, models of care). Must include preliminary and/or published data collected by the research team that support the rationale for the proposed study. Value: Up to USD $1.4M for up to 4 years. • Pain Management Collaboratory Award: Supports large-scale multi-centered pragmatic clinical trials of evidence-based nonpharmacological and/or multimodal approaches to pain management within Military and Veteran relevant health care systems. Participation in the National Institutes of Health – Department of Defense – Department of Veterans Affairs Pain Management Collaboratory including associated working groups and cross project initiatives is expected. Value: Planning Phase Base Award: Up to USD $500,000 for up to 15 months; Clinical Trial Phase Award: Up to USD $3.0M for up to 4 years. | TBA | |
| International | Solving Kids' Cancer Therapeutic Development Initiative (TDI) | $50,000 to $500,000 USD for up to 2 years. | Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. Priority is given to proposals that introduce novel therapeutic agents and modalities and have a strong potential to improve treatment outcomes. | Preliminary Proposal Deadline: Rolling | |
| International | Össur Orthopaedic Research Grant Program | -- | This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics. | Rolling Deadline | |
| International | Gateway for Cancer Research | GFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years. SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years. | Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine. • GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world. • GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. • SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. • GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps. | • GFCR Grant Program: Rolling Deadline • GFCR Integrative Program: Rolling Deadline • SIO / Gateway Integrative Research Grant Program: Rolling Deadline • GFCR Decentralized (DCTI) Grant Program: Rolling Deadline | |
| International | Aesculap Implant Systems Investigator-Initiated Study Program (IIS) | Dependent on the type of research and availability of support. | This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics. | Continuous | |
| International | Bausch + Lomb Grants | -- | • Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health. • Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers’ standard of care, efficacy, patient satisfaction, safety and vision performance. | Rolling submission. Allow 6-12 weeks for proposal review and decision. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on HIV-associated Malignancies | -- | This NOSI calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of malignancies, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. Applications responding must propose pioneering research that aligns with the HIV/AIDS Research Priorities here. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment | -- | This is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. Understanding the heterogeneity of obesity is necessary for precision and targeted implementation of obesity prevention and treatment interventions. Responsive proposals would include those aiming to investigate biological or nonbiological mechanisms through which adiposity differentially affects health. Other responsive applications might include those evaluating heterogeneity in response to obesity prevention and treatment, based on biological (e.g., genetic), behavioral, and/or racial/ethnic factors. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2027. No applications will be accepted on or after September 8, 2027. | |
| NIH | NIH Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes: Various Opportunities | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. • R01 Clinical Trial Not Allowed • R21 Clinical Trials Not Allowed | • R01 Clinical Trial Not Allowed: Deadlines: October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025; February 5, 2026; June 5, 2026. • R21 Clinical Trials Not Allowed: Deadlines: October 16, 2023; February 16, 2024; June 16, 2024; October 16, 2024; February 16, 2025; June 16, 2025; October 16, 2025; February 16, 2026; June 16, 2026. | |
| NIH | NIH R21: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | -- | The purpose of is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). | This notice applies to due dates on or after October 16, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | -- | This is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The National Library of Medicine (NLM) and National Institute of Mental Health (NIMH) seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. | October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025; June 5, 2026; October 5, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. • R01 Clinical Trial Optional: Deadlines: October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025; February 5, 2026; June 5, 2026. • R21 Clinical Trial Optional: High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism, while applications with preliminary data should apply to the R01 mechanism. | Deadlines: October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025; February 5, 2026; June 5, 2026 | |
| NIH | NIH Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation | -- | The scientific objective is to support projects to explore HIV cure approaches administered during active HIV/SHIV/SIV infection, prior to or around the time of ART initiation, before viral loads are completely suppressed, or after an analytical treatment interruption to potentially enhance the ongoing immune response and prevent additional reservoir seeding. The curative approaches studied should be experimental, innovative, and not yet approved by the FDA or a foreign regulatory agency for an HIV indication. | This notice applies to due dates on or after January 7, 2023 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | -- | The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. | April 6, 2023; August 4, 2023; December 6, 2023. | |
| NIH | NIH HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions | -- | This seeks to support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). | December 14, 2023. | |
| • R01 Clinical Trial Optional: The purpose is to support secondary analysis of data from relevant clinical projects and archives, and to support new hypothesis-clarifying studies to identify how people with OUD-AUD are being treated and associated treatment practices for this population. | |||||
| • R34 Clinical Trial Optional: The purpose is to support clinical research project development, including piloting study design and research protocols, subject recruitment, and initiating data collection and analysis pertinent to studying treatment practices for people with OUD-AUD. | |||||
| NIH | NIH Notice of Funding Opportunity (NOFO): Devide Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | -- | This seeks to support research into neuromodulatory technologies to treat SUDs. These technologies include, but are not limited to, transcranial magnetic stimulation, transcranial direct current stimulation, vagal stimulation, deep-brain stimulation, focused ultrasound, and others. Also of interest are technologies that may not directly modify neuronal function but report on or alter neurophysiology that affect outcomes. Activities supported under this NOFO can be found here. | December 18, 2023; August 13, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) | -- | This NOFO solicits applications to that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. | Letter of Intent: January 19, 2024 Full Application: February 21, 2024 | |
| NIH | NIH Computational Models of Influenza Immunity (U01 Clinical Trial Not Allowed) | -- | This invites applications for the Computational Models of Influenza Immunity (CMII) Cooperative Agreement Program. The program will employ computational modeling and immunologic studies to advance our understanding of the requirements for improving anti-influenza immunity, including inducing broad immune protection and enhancing immune durability. This program will help inform design of universal or improved seasonal flu vaccines. Projects may lead to a better understanding of how pre-existing immunity and repeat exposures (natural infection and/or vaccines) shape an individual’s immune “landscape.” Predictive modeling of adjuvants/vaccine formulations and experimental validation supported by this program should lead to enhanced host immune responses and universal or improved seasonal influenza vaccine efficacy. | January 26, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): BRAIN Initiative- Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) | -- | This NOFO solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative (The Brain Research through Advancing Innovative Neurotechnologies) or to enhance our understanding of the brain. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders. | May 9, 2023; October 13, 2023; June 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | -- | This NOSI will support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. | This notice applies to due dates on or after May 21, 2023 and subsequent receipt dates through May 8, 2026. | |
| NIH | NIH R21: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) | -- | The purpose of this is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. Example areas for tool and technology development can be found at the opportunity website. | June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; October 16, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Core Mission Areas | -- | This will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. | This notice applies to due dates on or after June 16, 2023 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | -- | This is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high impact, high risk nature of the research, preliminary data are not required. | August 2, 2023; August 2, 2024; August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment | -- | This NOSI solicits applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026 | |
| NIH | NIH NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) | -- | This encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the National Institute of Allergy and Infectious Diseases (NIAID) and considered high-priority by the Institute. | September 13, 2023; January 16, 2024; May 13, 2024; September 13, 2024; January 13, 2025; May 13, 2025; September 15, 2025; January 13, 2026; May 13, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional) | -- | This seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies. Investigators are encouraged to utilize lessons learned from ongoing or legacy cohort studies alongside other data sources to strengthen D&I research projects targeting PLWH. Further, there are opportunities to evaluate both the effectiveness and D&I outcomes of the selected EBIs, based on the level evidence to support their implementation. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026. | |
| NIH | NIH Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) | -- | This is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. his phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. | October 18, 2023; October 18, 2024. | |
| NIH | NIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | -- | This invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. | November 3, 2023; February 5, 2024; October 5, 2024; February 5, 2025; October 5, 2025; February 5, 2026. | |
| NIH | NIH Notice of Funding Opportunity: Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | -- | The objective is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. | December 7, 2023. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. | February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; October 16, 2024; February 16, 2025. | |
| NIH | NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | _ | The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. | February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024. | |
| NIH | NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) | -- | This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024. | |
| NIH | NIH Dissemination and Implementation Research in Health | -- | Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. • R01 Clinical Trial Optional • R03 Clinical Trial Not Allowed • R21 Clinical Trial Optional | R01 Clinical Trial Optional: June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025. R03 Clinical Trial Not Allowed: June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025. R21 Clinical Trial Optional: June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025. | |
| NIH | NIH Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment (R21/R33 Clinical Trial Not Allowed) | This encourages participatory data science and implementation science research to accelerate the implementation of more targeted and sustainable HIV interventions with the goals of (1) using data science methods to model complex systems, including social and structural determinants of health, to identify more targeted HIV prevention, treatment, and care interventions and implementation strategies; (2) using novel measurement approaches and modern statistical methods to evaluate the implementation of data-driven discoveries; (3) integrating meaningful engagement of community and implementing partners at every stage of the research. | November 22, 2023. | ||
| NIH | NIH NOFO - Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | -- | This seeks to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. | Letter of Intent: 30 days prior to the application due date. Full Application: Mulitple dates in 2024 through 2026. | |
| NIH | NIH HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. • R01 Clinical Trial Not Allowed • R21 Clinical Trial Not Allowed | February 1, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data | -- | The National Library of Medicine (NLM) invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools, whether the data are obtained from electronic health records, public health data sets, biomedical imaging, omics repositories, literature, and social media data, or other biomedical or social/behavioral data sets. Applications in response to this NOSI are expected to help address AI ethical issues and mitigate algorithm bias caused by data problems. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | -- | This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects. | February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | -- | National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior | -- | The eXplainable Artificial Intelligence (XAI) framework aims to provide strong predictive value along with a mechanistic understanding of AI solutions by combining machine learning techniques with effective explanatory techniques. This NOSI solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. | February 8, 2023; June 13, 2023; October 10, 2023; February 8, 2024; June 10, 2024; October 8, 2024; February 10, 2025. | |
| NIH | NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. | February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024. | |
| NIH | NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | -- | The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024. | |
| NIH | NIH Multi-Site Investigator-Initiated Clinical Trials: Various Opportunities | -- | These support investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI). Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025. | |
| NIH | NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | -- | This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI). | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025. | |
| NIH | NIH Dementia Care and Caregiver Support Intervention Research | -- | • R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the • NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care. • R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials. | February 10, 2023; October 10, 2023; February 13, 2024. | |
| NIH | NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. It does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. | February 13, 2023; June 12, 2023; October 10, 2023; February 13, 2024; June 12, 2024; October 10, 2024; February 13, 2025; June 12, 2025. | |
| NIH | NIH Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) | -- | This is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complications and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.The focus is on: • Development of Next-Generation HIV Therapies (drugs and biologics with improved safety and ease of use, e.g., sustained release antiretrovirals; novel HIV targets & inhibitors; novel immune-based therapies), • Development of Next-Generation HIV Prevention Strategies (e.g., long-acting, sustained release or multi-purpose prevention technologies), and • Development of New Treatments for HIV-associated comorbidities, coinfections, and complications. | February 13, 2024. | |
| NIH | NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities | -- | NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. • PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) • PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) • PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) • PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) • PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) • PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) • PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) • PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024. | |
| NIH | NIH High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | -- | This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. | February 15, 2023; August 15, 2023; February 15, 2024. | |
| NIH | NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | -- | The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice. | February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; October 18, 2024; February 19, 2025. | |
| NIH | NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) | -- | This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. | February 17, 2023; August 17, 2023; February 20, 2024; August 19, 2024; February 19, 2025. | |
| NIH | NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) | -- | This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. | February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024. | |
| NIH | NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | -- | This supports the phased development of in vivo assays to address translational gaps in treatment development for mental disorders. Support will be provided for assay development efforts that propose quantitative measures to assess alterations in neurophysiology/circuit activity that contribute to or reflect clinically relevant domains of function (e.g., cognitive function, impulsivity, motivation, etc.). It supports assays that measure brain functions that are evolutionarily conserved between a selected animal species and humans. | February 21, 2023; June 21, 2023; October 21, 2023; February 21, 2024; June 21, 2024; October 21, 2024; February 21, 2025; June 20, 2025. | |
| NIH | NIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | -- | This supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. | February 22, 2023; June 20, 2023; October 17, 2023; February 22, 2024; June 20, 2024; October 17, 2024; February 24, 2025; June 20, 2025; October 17, 2025. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | -- | This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. | February 24, 2023; June 26, 2023; October 25, 2023; February 27, 2024; June 25, 2024; October 25, 2024; February 25, 2025; June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research | -- | This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. | This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024. | |
| NIH | NIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. | March 1, 2023; September 1, 2023. | |
| NIH | NIH Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. | March 1, 2023; September 1, 2023. | |
| NIH | NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. Information about NIA's mission can be found on the NIA website. | March 7, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025. | |
| NIH | NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | -- | This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. | March 7, 2023; November 5, 2023; March 7, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data | -- | This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications. • R21 Clinical Trial Optional • R01 Clinical Trial Optional | March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Research on Current Topics in Alzheimer's Disease and Its Related Dementias | This invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding. • R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field. • R01 Clinical Trial Optional | March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024. | ||
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) | -- | The National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS, including Data Harmonization, Curation, and Analysis; Development of Biomarkers and Biomarker Signatures to Optimize Clinical Trials and Clinical Care Decisions; and Therapy Development for ALS. | This notice applies to due dates on or after March 14, 2023, and subsequent receipt dates through June 24, 2024. | |
| NIH | NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | -- | This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation. | March 15, 2023; March 15, 2024; March 14, 2025 | |
| NIH | NIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | -- | The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women’s Health (ORWH) are issuing this NOSI to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notices of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems | -- | The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. | • Population, Clinical and Applied Prevention Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2024. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, large-scale intervention efficacy or effectiveness trials, implementation science studies, or data science approaches to optimize HIV prevention, treatment, and care. • R01 Clinical Trial Optional: For applications with preliminary data or those including longitudinal analysis, advanced modeling, large-scale clinical trials or implementation science studies. • R21 Clinical Trial Optional: For exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques or models. • R34 Clinical Trial Optional: For applications proposing the initial development and pilot testing of a clinical trial or formative implementation research. | May 9, 2023; September 8, 2023; January 9, 2024; May 9, 2024; September 10, 2024; January 9, 2025; May 9, 2025; September 9, 2025; January 9, 2026. | ||
| NIH | NIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | -- | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC [National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA)]. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. | May 15, 2023; September 13, 2023; January 16, 2024; May 13, 2024; September 13, 2024; January 13, 2025; May 13, 2025; September 15, 2025; January 13, 2026 | |
| NIH | NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | -- | This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients. | May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy | -- | This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest | This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025. | |
| NIH | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. | June 6, 2023; October 6, 2023; February 6, 2024; June 10, 2024; October 8, 2024; February 7, 2025; June 6, 2025; October 7, 2025; February 6, 2026. | |
| NIH | NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) | -- | This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical). | June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024 | |
| NIH | NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) | -- | This supports interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive. | June 9, 2023; October 10, 2023. | |
| NIH | NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) | -- | The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. | June 9, 2023; and October 10, 2023. | |
| NIH | NIH Advancing Psychedelics Research for Treating Addiction: Various Opportunities | -- | • R01 Clinical Trial Not Allowed: This supports research to improve our understanding of psychedelic drug mechanisms in the context of substance use disorders (SUDs). This will also support the design and synthesis of chemical biology tools and probes to aid basic research on psychedelics and their translational pharmacology. • R61/R33 Clinical Trial Required: To encourage clinical research that will advance understanding of how SUD relevant cognitive, emotional, and social processes are modulated by Psychedelics. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving psychedelics. • R61/R33 Basic Experimental Study with Humans Required: To encourage clinical research that will advance understanding of how SUD relevant cognitive, emotional, and social processes are modulated by Psychedelics. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving psychedelics. | November 2, 2023. | |
| NIH | NIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities | -- | This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. • PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products. • PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. • PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. | June 21, 2023; June 21, 2024. | |
| NIH | NIH BRAIN Initiative: Targeted BRAIN Circuits Projects | -- | • R34 Clinical Trials Not Allowed: For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying hat, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01 • R01 Clinical Trial Not Allowed: For research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. | R34 Clinical Trials Not Allowed: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024. R01 Clinical Trial Not Allowed: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment | -- | This NOSI solicits theoretically- and empirically-driven research applications which will: 1) advance measurements and understanding of HIV-related ISD or intersectional social-structural factors to examine the mechanisms and pathways by which they are barriers to HIV prevention and HIV treatment; 2) develop and test interventions to address their impact to improve HIV prevention and HIV treatment outcomes; or 3) conduct implementation science research of evidence-based interventions. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | -- | This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function. | September 12, 2023; September 12, 2024. | |
| NIH | NIH Tobacco Regulatory Science (R01 Clinical Trial Optional) | -- | This is to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). | October 6, 2023; May 6, 2024; October 4, 2024; May 2, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities | -- | This NOSI is intended to support the use of the telehealth interventions and tools aimed at the prevention, management and treatment of heart, lung, blood, and sleep conditions, and of cancer in rural communities. For the purpose of this NOSI, provider-to-provider telehealth (PPT) is defined broadly to include any health technology meant to connect healthcare providers to one another for the care of patients (e.g., video, chat or audio consults with a clinical specialist for patients under the care of a primary care clinician located in another healthcare facility). | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through October 9, 2026. | |
| NIH | NIH Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed) | Up to USD $1,000,000 for up to 4 years. | This is to encourage research that will integrate and harmonize existing large prevention trial data sets. The data sets should consist of well-characterized participant-level data for interventions implemented earlier in life to examine whether they reduce risk for later suicide, including suicidal thoughts and behaviors — fatal and nonfatal (STB), and related external injuries (e.g., nonfatal SUD/OUD/accidents, and all-cause mortality (e.g., National Death Index)). | October 10, 2023. | |
| NIH | NIH BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) | -- | This is for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. | October 13, 2023. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women | -- | This NOFO invites applications to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available. • R21 Clinical Trial Optional: High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. • R01 Clinical Trial Optional: Applications with preliminary data and/or those including longitudinal analysis or proposing a large-scale clinical trial should consider using the R01 mechanism. • R34 Clinical Trial Optional: Applicants proposing to develop and pilot test an intervention should consider the R34 mechanism. | November 23, 2023. | |
| NIH | NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | -- | This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). | December 7, 2023; December 7, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Biotypes of CNS Complications in People Living with HIV (P01 Clinical Trial Not Allowed) | -- | This seeks to understand the heterogeneity of central nervous system (CNS) outcomes in people with HIV on Anti-retroviral therapy (ART), employing quantitative assessments that are linked to psychopathology to identify distinct disease phenotypes, known as biotypes. | December 12, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | -- | This is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms. | This Notice applies to due dates until March 9, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | -- | The purpose of this Notice is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. | This notice applies to subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research | -- | This invites applications for small research grants that align with the goals of the National Academy of Medicine's Healthy Longevity Grand Challenge, as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). | This Notice applies to due dates on or after July 16, 2023 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings | -- | The purpose is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioral (MEB) health in school settings. | This Notice applies to due dates until June 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | -- | This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. | This notice applies to subsequent receipt dates through August 1, 2025. | |
| NIH | NIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed) | -- | This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available. | June 14, 2023; June 14, 2024. | |
| NIH | Occupational Safety and Health Research (R01) | -- | The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. | Standard dates apply until November 18, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders | -- | The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments. | This notice applies to subsequent receipt dates through December 7, 2023. | |
| NIH | NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) | -- | This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH). | • PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023. • PAR-21-343: Application. Deadlines: April 18, 2022; April 18, 2023; April 18, 2024. | |
| NIH | NIH Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer | -- | This intends to focus on basic mechanistic and translational studies to investigate HIV and cancer in underrepresented groups. Underrepresented groups include racial, ethnic, and gender minorities, including underserved minorities living in geographical areas that have high numbers of new HIV infections (e.g., Southern and some urban areas in the United States, international sites that have higher rates of underlying HIV infection). Mechanistic and/or translational studies that examine how different comorbidities, associated behaviors, and other disorders (e.g., diabetes, smoking, injecting drug users, obesity, etc.), contribute to the initiation, progression and disease sequelae in underserved populations may be proposed. • R21 Clinical Trial Not Allowed • R01 Clinical Trial Not Allowed | December 15, 2023. | |
| NIH | NIH BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Not Allowed) | -- | This supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors. | February 17, 2023; February 15, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes | -- | This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to: • Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an “accelerated aging” phenotype; • Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes; • Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors; • Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints; • Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and • Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging. | This notice applies to receipt dates through January 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | -- | This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data. | This notice applies to subsequent receipt dates through January 8, 2024. | |
| NIH | NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) | -- | This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. | Standard AIDS dates apply until January 8, 2024. | |
| NIH | NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) | -- | This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities. | Standard AIDS dates apply until January 8, 2024. | |
| NIH | NIH Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | -- | This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. | Standard dates apply until January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders | -- | National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions. | This notice applies to receipt dates through January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition | - | This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. | This notice applies to subsequent receipt dates through January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care | -- | This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. | This notice applies to subsequent receipt dates through March 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | -- | This encourages grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms. | This notice applies to subsequent receipt dates through March 9, 2024. | |
| NIH | NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes | -- | National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden. PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions | Standard dates apply until March 17, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies | -- | National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged. National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV | -- | This is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research | -- | This is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). | This Notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) | -- | This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. | Standard dates apply until May 8, 2024. | |
| NIH | NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) | -- | This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. | Standard dates apply until May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis | -- | This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. | This notice applies to receipt dates through May 8, 2024. | |
| NIH | NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities | Up to USD $50,000 per year for up to 2 years. | PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission. | Standard dates apply until May 8, 2024. | |
| NIH | NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment | -- | The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization. • PAR-21-166: R01 - Clinical Trial Not Allowed • PAR-21-206: R01 - Clinical Trial Optional | Standard dates apply until May 8, 2024. | |
| NIH | NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities | -- | The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. PAR-21-175 (R01 Clinical Trial Optional) PAR-21-176 (R21 Clinical Trial Optional) | Standard dates apply until May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide | -- | This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic. | This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities | -- | This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities. | This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure | -- | To address knowledge gaps that will improve HIV outcomes, this calls for research that will improve scientific understanding of health communication as it relates to ongoing HIV prevention, diagnosis, treatment and cure efforts, as well as research on communication, dissemination and implementation factors that are required for successful public understanding, acceptance and uptake of HIV-related interventions. | This notice applies to due dates on or after April 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities | -- | The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations. | This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health | -- | This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. | This notice applies to subsequent receipt dates through June 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) | -- | This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement. | This notice applies to receipt dates through July 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) | This NOSI supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with Substance Use Disorders. Applications responding to this must propose pioneering research that aligns with the NIH HIV/AIDS Research Priorities. | This notice applies to due dates on or after July 15, 2023 and subsequent receipt dates through August 15, 2025. | ||
| NIH | NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning | -- | This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI. | This notice applies to subsequent receipt dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 | -- | National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | -- | This NOSI encourages research to understand: • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection. • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana. • The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer. | This notice applies to due dates through September 8, 2024. | |
| NIH | NIH Basic Research in Cancer Health Disparities | -- | This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. • - R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities. • - R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. • - R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. | Standard dates apply until September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions | -- | National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research | -- | The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | -- | The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged. | This notice applies to subsequent receipt dates through October 9, 2024. | |
| NIH | NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) | -- | This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials | Standard dates apply until November 6, 2024. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. • R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21. • R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope. | Standard dates apply until January 8, 2025. | |
| NIH | NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest | -- | This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals. | This notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders | -- | NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. • R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism. • R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). | Standard dates apply until January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research | -- | National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities. | This Notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis | -- | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. | This notice applies to subsequent receipt dates through May 5, 2025. | |
| NIH | NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | -- | The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening | -- | This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. | This NOSI applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | -- | This encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees. At minimum, the proposed studies must: Include screening as a primary outcome; Inform the development of OR test an intervention or strategy that acts on at least two socioecological levels; and, Include OR test an intervention or strategy that demonstrates high potential for scalability and sustainability. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | -- | The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data. | Standard dates apply until May 8, 2025. | |
| NIH | NIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | -- | This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. | Standard due dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): BRAIN Initiative: Developing Data Archive, Informatics Tools and Data Standards for Brain Behavior Quantification and Synchronization (BBQS) | -- | The purpose of is to encourage new applications for developing informatics infrastructure for BBQS) research program of the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative. Specifically, the NOSI supports a) creation of data archive(s) to store and manage BBQS-relevant data; b) development of computational tools or software for analyzing, visualizing and integrating BBQS-related data, and for predicting and modeling the complex dynamics of the brain-behavior system; and c) establishment of data standards or ontologies that support the BBQS-related studies. | Submission of an application in response to this NOSI should use one of the following: BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed): June 9, 2023; October 13, 2023; June 7, 2024. BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed): June 14, 2023; June 14, 2024. BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional): July 14, 2023. | |
| NIH | NIH Informatics Technologies for Cancer Research and Management | -- | This invites applications for the development of innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. • Development of Innovative Informatics Methods and Algorithms (R21 Clinical Trial Optional) This supports the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. • Early-Stage Development (U01 Clinical Trial Optional) For initial tool development or the significant modification of existing tools for new applications. • Advanced Development (U24 Clinical Trial Optional) For emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. • Sustained Support (U24 Clinical Trial Optional) This focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. | June 13, 2023; November 17, 2023. | |
| NIH | NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | -- | This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. | This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations | -- | This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. Investigators will be required to engage community partners at the onset and throughout their research project. | This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | -- | This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics). | This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | -- | The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities. | This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | -- | This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. | This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Bioengineering Research Grants (BRG) | -- | This is to encourage collaborations- between life science and physical science- that: 1) apply a multidisciplinary bioengineering approach to solve biomedical problems; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. • R01 Clinical Trial Not Allowed: This is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science. • R01 Clinical Trial Optional: This will support clinical trials that test functionality or validate performance in the chosen setting. | Standard due dates apply until September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | -- | This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records). | This notice applies to subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information | -- | This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making. | This notice applies to subsequent receipt dates through September 24, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes | -- | This encourages novel intervention research aimed at developing, refining, adapting, and testing interventions focused on preventing violence or addressing acute and chronic effects of violence on physical and behavioral health. Effectiveness, implementation, and hybrid effectiveness-implementation designs are encouraged, as appropriate to the research questions proposed. | This notice applies to subsequent receipt dates through October 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Family Support and Rejection in the Health and Well-Being of SGM Populations | -- | The goal of this NOSI is to boost research on the impact and consequences of family rejection and family support on the health and well-being of sexual and gender minority (SGM) persons across the life course. Research proposed under this NOSI may include behavioral, social, clinical, implementation, basic, complementary, integrative, and any other relevant research approaches that probe the influences of family rejection, acceptance, affirmation, support, and belonging on the immediate and long-term health and health outcomes of SGM individuals at any life stage. | May 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood | -- | This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases. | This notice applies to subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Parent Announcements | -- | • - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) • - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) • - NIH Research Project Grant (Parent R01 Clinical Trial Required) • - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) | Standard dates apply unless otherwise stated. |
